PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Betahistine hydrochloride - Meniere's disease
PAD Profile : Betahistine hydrochloride - Meniere's disease
Keywords :
Meniere's syndrome, vertigo, hearing loss, tinnitus, vestibular disorders
Brand Names Include :
Serc
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Surrey & North West Sussex Area Prescribing Committee (APC) recommend the prescribing o betahistine for the treatment of Meniere's Disease in line with NICE Clinical Knowledge Summaries (CKS) https://cks.nice.org.uk/menieres-disease
NOTE - the branded product, Serc, was considered BLACK at the PCN in May 2017. https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/5580
Associated BNF Codes
04. Central Nervous System
04.06.00. Drugs used in nausea and vertigo